高级检索

索拉非尼联合经导管肝动脉化疗栓塞治疗中晚期肝癌的疗效分析

Efficacy of sorafenib combined with transcatheter arterial chemoembolization in treatment of patients with middle and advanced hepatocellular carcinoma

    摘要
  • 摘要:
      目的  观察索拉非尼联合经导管肝动脉化疗栓塞(TACE)治疗中晚期肝癌患者的临床疗效。
      方法  将150例中晚期肝癌患者分为单纯治疗组和联合介入组。比较2组治疗后的疗效，不良反应以及1、3、5年存活率。比较2组治疗前后血清磷脂酰肌醇聚糖3(GPC3)、转化生长因子结合蛋白2(LTBP2)表达情况。
      结果  联合介入组疗效优于单纯治疗组，3、5年存活率高于单纯治疗组，血清GPC3、LTBP2表达水平以及不良反应发生率低于单纯治疗组，差异均有统计学意义(P < 0.05)。
      结论  索拉非尼联合TACE可以有效延长中晚期肝癌患者的存活时间，且不良反应发生率较低。

     

    Abstract:
      Objective  To observe the clinical efficacy of sorafenib combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with middle and advanced liver cancer.
      Methods  Totally 150 patients with middle and advanced liver cancer were divided into simple treatment group and combined intervention group. The efficacy, adverse reactions and 1-, 3-, 5-year survival rates were compared between the two groups. The expressions of serum glypican-3 (GPC3) and latent transforming growth factor beta binding protein 2 (LTBP2) were compared between the two groups before and after treatment.
      Results  Efficacy of the combined intervention group was significantly better than that of the simple treatment group, the 3- and 5-year survival rates were significantly higher than that of the simple treatment group, and the serum levels of GPC3 and LTBP2 as well as the incidence of adverse reactions were significantly lower than those of the simple treatment group (P < 0.05).
      Conclusion  Sorafenib combined with TACE can effectively prolong the survival time of patients with middle and advanced liver cancer, and the incidence of adverse reactions is low.

     

    • HTML全文
    • 参考文献(14)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回